Advertisement

Pharma Learns from Carmakers

Some Big Pharma companies are turning to the world’s automobile makers for advice on innovation and profitability.

By | December 14, 2011

Assembly line at Hyundai Motor Company’s car factory in Ulsan, South Korea WIKIMEDIA COMMONS, TANELI RAJALA

In the past couple of years, big time drugmakers, including GlaxoSmithKline and AstraZeneca, have begun to turn to an unusual advisor for support: automobile manufacturers. While the products of the two industries may have little in common, the structures of the companies are becoming more and more similar.

In 2009, AstraZeneca looked to Jaguar Land Rover, part of India's Tata Motors, for manufacturing advice, Reuters reported. And just a few months ago, GlaxoSmithKline teamed up with McLaren’s Formula One engineers for input on innovation and overall process procedures.

The trend may stem from the rising pressures on the pharmaceutical industry, as patents for big name brand drugs expire and the regulatory landscape makes it increasingly difficult for new drugs to enter the market. "The good old days of the pharmaceutical industry are gone forever," according to a report issued by management consulting firm McKinsey last week.

The situation parallels that of the automobile industry not too long ago, which is precisely why pharma companies are coming here for advice. The depressed economy forced car manufacturers to streamline the process and cut significant costs by outsourcing and down-sizing. While carmakers once did much of the work in-house, they now take on a more administrative role, coordinating contractors and suppliers who do the bulk of the work. As a result, the average product development time in the industry has fallen by nearly 30 percent, according to Porsche. In pharma, on the other hand, the average product development time has risen by 30 percent.

"In terms of production costs, the auto industry may be a model for other industries,” Reto Hess, who coordinates analysis of global car makers at Credit Suisse Private Banking, told Reuters. “The amount of high tech that is offered at affordable prices in today's cars is remarkable." For pharma, this could mean outsourcing more and more of the work to CROs and licensed biotech companies, as research budgets continue to dwindle.

Advertisement

Add a Comment

Avatar of: You

You

Processing...
Processing...

Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo

Follow The Scientist

icon-facebook icon-linkedin icon-twitter icon-vimeo icon-youtube
Advertisement

Stay Connected with The Scientist

  • icon-facebook The Scientist Magazine
  • icon-facebook The Scientist Careers
  • icon-facebook Neuroscience Research Techniques
  • icon-facebook Genetic Research Techniques
  • icon-facebook Cell Culture Techniques
  • icon-facebook Microbiology and Immunology
  • icon-facebook Cancer Research and Technology
  • icon-facebook Stem Cell and Regenerative Science
Advertisement
Advertisement
Life Technologies